I think we need to stop seeing ither drugs as competitors. There is a very real chance (although not yet tested) that ATL1102 may improve the response of these other drugs. A small preclinical trial by PER shows that treatment with other drugs does not stop ATL1102 from working its magic. And it has been hypothesised that ATL1102 may even improve these other drugs hen used in combination.
ATL1102 is being trialed as a monotherapy, and the previous trial showed results not before seen in DMD (small cohort though). Perhaps combination treatments opens even more market share?
PER Price at posting:
9.0¢ Sentiment: Buy Disclosure: Held
